Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination
- 1 June 2011
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 69 (1) , 155-164
Abstract
Purpose Inhibition of DNA repair is emerging as a new therapeutic strategy for cancer treatment. One promising target is DNA-PK, a pivotal kinase in double-strand break repair. The purpose of this study was to further characterise the activity of the DNA-PK inhibitor NU7441, giving some new insights into the biology of DNA-PK. Methods We used NU7441, a potent DNA-PK inhibitor, to evaluate potential pharmacodynamic markers of DNA-PK inhibition, inhibition of DNA repair and chemo- and radio-potentiation in isogenic human cancer cells proficient (M059-Fus1) and deficient (M059 J) in DNA-PK. Results NU7441 strongly inhibited DNA-PK in cell lines (IC50 = 0.3 μM) but only weakly inhibited PI3 K (IC50 = 7 μM). The only available anti-phospho-DNA-PK antibody also recognised some phosphoprotein targets of ATM. NU7441 caused doxorubicin- and IR-induced DNA DSBs (measured by γ-H2AX foci) to persist and also slightly decreased homologous recombination activity, as assessed by Rad51 foci. Chemo- and radio-potentiation were induced by NU7441 in M059-Fus-1, but not in DNA-PK-deficient M059 J cells. DNA-PK was highly expressed in a chronic lymphocytic leukaemia sample but undetectable in resting normal human lymphocytes, although it could be induced by PHA-P treatment. In K652 cells, DNA-PK expression was not related to cell cycle phase. Conclusion These data confirm NU7441 not only as a potent chemo- and radio-sensitiser clinical candidate but also as a powerful tool to study the biology of DNA-PK.Keywords
This publication has 27 references indexed in Scilit:
- Mechanisms of double-strand break repair in somatic mammalian cellsBiochemical Journal, 2009
- Choreography of recombination proteins during the DNA damage responseDNA Repair, 2009
- DNA-Dependent Protein Kinase Is a Therapeutic Target and an Indicator of Poor Prognosis in B-Cell Chronic Lymphocytic LeukemiaClinical Cancer Research, 2008
- Mechanism and Regulation of Class Switch RecombinationAnnual Review of Immunology, 2008
- DNA Protein Kinase–Dependent G2 Checkpoint Revealed following Knockdown of Ataxia-Telangiectasia Mutated in Human Mammary Epithelial CellsCancer Research, 2008
- Autophosphorylation of DNA-PKCS regulates its dynamics at DNA double-strand breaksJournal of Cell Biology, 2007
- Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone librariesBioorganic & Medicinal Chemistry Letters, 2004
- The DNA-dependent protein kinaseGenes & Development, 1999
- DNA-Dependent Protein Kinase Activity Correlates With Clinical and In Vitro Sensitivity of Chronic Lymphocytic Leukemia Lymphocytes to Nitrogen MustardsBlood, 1998
- The SCID Mouse Mutant: Definition, Characterization, and Potential UsesAnnual Review of Immunology, 1991